Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.
By replicating native human biology, the intestinal stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.
The RepliGut® Platform
RepliGut® is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.
With a scalable platform, actionable data, high throughput screening to test thousands of compounds, and an unrivaled biobank, RepliGut® is the future of in vitro testing during drug development.
The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.
NEWS AND ARTICLES
November 4, 2021
Webinar: Studying the Responses to Cytokines Using Novel In Vitro Stem Cell Platforms
Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.Watch Video
August 5, 2021
The Power Of RepliGut® In Vitro Intestinal Stem Cell Models
Both current in vitro and in vivo models used in the development of candidate therapies for the treatment of intestinal diseases have severe limitations. RepliGut®, an in vitro human intestinal epithelial stem cell model, addresses many of these issues and has significant potential to reduce the time and cost of drug development. This model may even help to identify optimal therapies for individual patients.Read More
Have a question? Want to stay informed about Altis, RepliGut, and more platforms currently under development? Send us a message!